These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20357369)

  • 1. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes.
    Walter M; Kaupper T; Adler K; Foersch J; Bonifacio E; Ziegler AG
    Diabetes Care; 2010 Jul; 33(7):1443-8. PubMed ID: 20357369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
    Walter M; Philotheou A; Bonnici F; Ziegler AG; Jimenez R;
    Diabetes Care; 2009 Nov; 32(11):2036-40. PubMed ID: 19690081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI).
    Pitocco D; Crinò A; Di Stasio E; Manfrini S; Guglielmi C; Spera S; Anguissola GB; Visalli N; Suraci C; Matteoli MC; Patera IP; Cavallo MG; Bizzarri C; Pozzilli P;
    Diabet Med; 2006 Aug; 23(8):920-3. PubMed ID: 16911633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA).
    Li X; Liao L; Yan X; Huang G; Lin J; Lei M; Wang X; Zhou Z
    Diabetes Metab Res Rev; 2009 Jul; 25(5):411-6. PubMed ID: 19488999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial.
    Bizzarri C; Pitocco D; Napoli N; Di Stasio E; Maggi D; Manfrini S; Suraci C; Cavallo MG; Cappa M; Ghirlanda G; Pozzilli P;
    Diabetes Care; 2010 Sep; 33(9):1962-3. PubMed ID: 20805274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.
    Gabbay MA; Sato MN; Finazzo C; Duarte AJ; Dib SA
    Arch Pediatr Adolesc Med; 2012 Jul; 166(7):601-7. PubMed ID: 22751874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes.
    Napoli N; Strollo R; Pitocco D; Bizzarri C; Maddaloni E; Maggi D; Manfrini S; Schwartz A; Pozzilli P;
    PLoS One; 2013; 8(2):e56488. PubMed ID: 23437144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
    Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
    Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes.
    Rother KI; Brown RJ; Morales MM; Wright E; Duan Z; Campbell C; Hardin DS; Popovic J; McEvoy RC; Harlan DM; Orlander PR; Brod SA
    Diabetes Care; 2009 Jul; 32(7):1250-5. PubMed ID: 19564474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.
    Radtke MA; Nermoen I; Kollind M; Skeie S; Sørheim JI; Svartberg J; Hals I; Moen T; Dørflinger GH; Grill V
    Diabetes Care; 2010 Mar; 33(3):589-94. PubMed ID: 20028939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
    Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
    Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
    von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
    Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes.
    Ataie-Jafari A; Loke SC; Rahmat AB; Larijani B; Abbasi F; Leow MK; Yassin Z
    Clin Nutr; 2013 Dec; 32(6):911-7. PubMed ID: 23395257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; Bianchi L; Bonaventura A; Romano D; Cicero AF; Maffioli P
    Diabetes Technol Ther; 2012 Jun; 14(6):475-84. PubMed ID: 22512264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 12 weeks high dose vitamin D3 treatment on insulin sensitivity, beta cell function, and metabolic markers in patients with type 2 diabetes and vitamin D insufficiency - a double-blind, randomized, placebo-controlled trial.
    Kampmann U; Mosekilde L; Juhl C; Moller N; Christensen B; Rejnmark L; Wamberg L; Orskov L
    Metabolism; 2014 Sep; 63(9):1115-24. PubMed ID: 25044176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients.
    Casas R; Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
    Front Immunol; 2020; 11():564921. PubMed ID: 33162978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS.
    Mari A; Rosenstock J; Ma X; Li YG; Jackson JA
    Endocr Pract; 2015 Dec; 21(12):1344-52. PubMed ID: 26307903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes.
    Gitelman SE; Evans-Molina C; Guolo A; Mari A; Ferrannini E
    Diabetes; 2023 Sep; 72(9):1289-1296. PubMed ID: 37368990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of interventions to preserve insulin-secreting β-cell function in people newly diagnosed with type 1 diabetes: Results from intervention studies aimed at improving glucose control.
    Narendran P; Tomlinson C; Beese S; Sharma P; Harris I; Adriano A; Maggs F; Burrows M; Nirantharakumar K; Thomas N; Price MJ; Andrews RC; Moore DJ
    Diabet Med; 2022 Jan; 39(1):e14730. PubMed ID: 34676911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.